Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 3Congenital Abnormalities 3Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Carcinoma, Hepatocellular 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Sorafenib 52pembrolizumab 26Nivolumab 20Bevacizumab 19Radiosurgery 17Doxorubicin 12atezolizumab 9Erlotinib Hydrochloride 9lenvatinib 8cabozantinib 7Magnetic Resonance Spectroscopy 7tremelimumab 6durvalumab 6Ramucirumab 6Radiofrequency Ablation 6Cisplatin 6Sunitinib 5tislelizumab 4regorafenib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Everolimus 4Capecitabine 4nintedanib 3fluoromisonidazole 3carotuximab 3bavituximab 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × Pravastatin × Clear all
NCT03219372 2021-01-22

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Cedars-Sinai Medical Center

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡